AllPennyStocks.com Novo’s 2027 Growth Rebound Faces Fresh Doubts From Deutsche Bank – Even As China Wegovy Milestone Offers Retail Hope
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Novo’s 2027 Growth Rebound Faces Fresh Doubts From Deutsche Bank – Even As China Wegovy Milestone Offers Retail Hope

Deutsche Bank said Ziltivekimab is ‘now effectively out of the picture’ after the cardiovascular disease therapy failed a late-stage trial.

Other Penny Stock Movers

$500 Million AI Merger Sends This Microcap Soaring
Historic Gold Ground Gets a Fresh Drill Test
Washington Is Financing Critical-Mineral Projects. What Will Canada Do?
Most Popular
{{ index + 1 }}
AllPennyStocks.com Favorites


Back to Top